Morning Overview on MSN
The first cellular age-reversal therapy has been cleared for human trials
Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...
Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...
Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...
A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...
Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...
An experimental MeiraGTx gene therapy that has clinical data showing reversal of blindness in children born with a rare, inherited eye disorder is heading to Eli Lilly. According to the terms of the ...
Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...
Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.
Prior clinical successes with gene therapy for one of these diseases has raised hopes for patients and families affected by other such diseases, " says Editor-in-Chief Terence R. Flotte, MD, Celia and ...
Happily on MSN
6-year-old girl regains vision through gene therapy
A 6-year-old girl with a rare inherited blindness regained vision through gene therapy, helping her see in low light again.
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results